处方药物审查：贝曲西班
Formulary Drug Review: Betrixaban.
作者信息
Baker Danial E
机构信息
Washington State University, Spokane, USA.
出版信息
Hosp Pharm. 2018 Feb;53(1):29-37. doi: 10.1177/0018578717739397. Epub 2017 Nov 6.
Abstract
Each month, subscribers to receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of publishes selected reviews in this column. For more information about , contact Wolters Kluwer customer service at 866-397-3433.
摘要
每月，订阅者会收到5至6篇关于新发布或处于3期临床试验后期阶段药物的详细专题论文。这些专题论文面向药学与治疗学委员会。订阅者还会每月收到1页关于对议程以及药房/护理在职培训有用药物的总结专题论文。每月还会提供一份全面的目标药物利用评估/用药评估（DUE/MUE）。订阅后，专题论文可供订阅者在线获取。专题论文可定制以满足机构需求。通过合作，出版方会在本专栏发表精选评论。如需了解更多关于……的信息，请致电866 - 397 - 3433联系威科集团客服。
相似文献
1
Formulary Drug Review: Betrixaban.处方药物审查：贝曲西班
Hosp Pharm. 2018 Feb;53(1):29-37. doi: 10.1177/0018578717739397. Epub 2017 Nov 6.
2
Eteplirsen.依特普瑞森
Hosp Pharm. 2017 Apr;52(4):302-305. doi: 10.1310/hpj5204-302.
3
Formulary Drug Review: Edaravone.处方药物审查：依达拉奉
Hosp Pharm. 2017 Dec;52(11):732-736. doi: 10.1177/0018578717734877. Epub 2017 Oct 9.
4
Formulary Drug Review: Ocrelizumab.处方药物评审：奥瑞珠单抗
Hosp Pharm. 2017 Oct;52(9):599-606. doi: 10.1177/0018578717731733. Epub 2017 Sep 17.
5
Formulary Drug Review: Etelcalcetide.处方药物评审：依特卡肽
Hosp Pharm. 2017 Nov;52(10):669-674. doi: 10.1177/0018578717733478. Epub 2017 Sep 25.
6
Omadacycline.奥马环素
Hosp Pharm. 2019 Apr;54(2):80-87. doi: 10.1177/0018578718823730. Epub 2019 Jan 22.
7
Angiotensin II.血管紧张素II
Hosp Pharm. 2018 Jul;53(4):230-233. doi: 10.1177/0018578718778224. Epub 2018 May 24.
8
Formulary Drug Review: Sufentanil Sublingual.处方药物评审：舒芬太尼舌下给药制剂
Hosp Pharm. 2019 Aug;54(4):222-228. doi: 10.1177/0018578719851726. Epub 2019 May 29.
9
Sugammadex.舒更葡糖钠
Hosp Pharm. 2016 Jul;51(7):585-96. doi: 10.1310/hpj5107-585.
10
Insulin Degludec/Liraglutide.德谷胰岛素/利拉鲁肽
Hosp Pharm. 2017 May;52(5):374-380. doi: 10.1177/0018578717715383. Epub 2017 May 1.
引用本文的文献
1
Predicting drug-drug interactions and optimal dosing of betrixaban with physiologically based pharmacokinetic modeling in patients with renal impairment who were coadministered with P-glycoprotein inhibitors.在合并使用P-糖蛋白抑制剂的肾功能不全患者中，通过基于生理的药代动力学模型预测贝曲西班的药物相互作用和最佳剂量。
J Int Med Res. 2025 Jun;53(6):3000605251346587. doi: 10.1177/03000605251346587. Epub 2025 Jun 6.
2
Comparison of Pregabalin and Midazolam as Premedication in Children Undergoing General Anesthesia for Dental Treatment.普瑞巴林与咪达唑仑作为牙科治疗全身麻醉儿童术前用药的比较。
Anesth Pain Med. 2024 Dec 15;14(6):e149486. doi: 10.5812/aapm-149486. eCollection 2024 Dec.
3
Drug-Drug Interactions with Direct Oral Anticoagulants.药物-药物相互作用与直接口服抗凝剂。
Clin Pharmacokinet. 2020 Aug;59(8):967-980. doi: 10.1007/s40262-020-00879-x.
本文引用的文献
1
Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.急性病成年患者中延长剂量的贝曲沙班与标准剂量依诺肝素所致致命或不可逆事件的比较：APEX试验子研究
J Am Heart Assoc. 2017 Jul 11;6(7):e006015. doi: 10.1161/JAHA.117.006015.
2
The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.在急性内科疾病患者中使用延长疗程的贝曲西班预防静脉血栓栓塞（APEX）试验中，全剂量与减少剂量贝曲西班的安全性和有效性。
Am Heart J. 2017 Mar;185:93-100. doi: 10.1016/j.ahj.2016.12.004. Epub 2016 Dec 18.
3
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).延长疗程贝曲西班相对于住院内科患者标准剂量依诺肝素降低卒中风险：APEXX 试验亚组研究（急性内科疾病静脉血栓栓塞预防用延长疗程贝曲西班）。
Circulation. 2017 Feb 14;135(7):648-655. doi: 10.1161/CIRCULATIONAHA.116.025427. Epub 2016 Nov 14.
4
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.急性病医学患者贝曲西班的延长血栓预防。
N Engl J Med. 2016 Aug 11;375(6):534-44. doi: 10.1056/NEJMoa1601747. Epub 2016 May 27.
5
Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.抗栓治疗 VTE 疾病：CHEST 指南和专家小组报告。
Chest. 2016 Feb;149(2):315-352. doi: 10.1016/j.chest.2015.11.026. Epub 2016 Jan 7.
6
Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.口服直接Xa因子抑制剂与依诺肝素用于髋或膝关节置换术后血栓预防：系统评价、传统Meta分析、剂量反应Meta分析和网状Meta分析。
Thromb Res. 2015 Dec;136(6):1133-44. doi: 10.1016/j.thromres.2015.10.009. Epub 2015 Oct 20.
7
Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism.贝曲西班简介及其在预防和治疗静脉血栓栓塞中的潜力。
Vasc Health Risk Manag. 2015 Jun 26;11:343-51. doi: 10.2147/VHRM.S63060. eCollection 2015.
8
Reversal of anticoagulants: an overview of current developments.抗凝剂的逆转：当前进展概述
Thromb Haemost. 2015 May;113(5):931-42. doi: 10.1160/TH14-11-0982. Epub 2015 Apr 2.
9
The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study.急性重病静脉血栓栓塞症预防的贝曲西班延长疗程设计和原理（APEX）研究。
Am Heart J. 2014 Mar;167(3):335-41. doi: 10.1016/j.ahj.2013.11.006. Epub 2013 Dec 10.
10
Monitoring plasma levels of factor Xa inhibitors: how, why and when?监测 Xa 因子抑制剂的血药浓度：方法、原因及时机？
Expert Rev Hematol. 2013 Apr;6(2):155-64. doi: 10.1586/ehm.13.11.
Zotero 插件